Dr. Phoenix A Ho | Seattle Children's Hospital

Phoenix A. Ho, MD

On staff since July 2009

Academic Title: Acting Assistant Professor

"Being diagnosed with cancer is a life-changing event. Children are remarkable people; it's an honor to take care of them and witness the strength, spirit, resilience and sense of humor with which they face adversity. At Children's, I'm privileged to be part of a comprehensive team, all working together to provide excellent care for our patients and their families during difficult times. Also, research is such an important part of what we do. My research focus is childhood leukemia, where we are working in the lab to understand the causes of the disease. We hope to translate this knowledge into new leukemia treatments that are more effective and better tolerated."

Phoenix A. Ho, MD, is attending physician at Seattle Children’s Hospital, acting instructor in the Division of Pediatric Hematology/Oncology at the University of Washington School of Medicine, and research associate in the Clinical Research Division at the Fred Hutchinson Cancer Research Center (FHCRC).

His clinical interests include the treatment of high-risk leukemia, including relapsed and refractory disease, while his research focus is the molecular biology of acute myeloid leukemia (AML). His interests include the molecular characterization of pediatric AML for the purposes of disease classification and risk stratification, and his work has included the study of mutations in leukemia-associated transcription factor genes such as CEBPA and WT1. Ho is also studying de-regulated signal transduction in AML, with a focus on the PI3K/Akt pathway. His goal is to translate his work into new treatments and better outcomes for children with AML.

Recommendations

Be the first to recommend Dr. Phoenix Ho

Overview
Awards and Honors
Publications
Research Funding

Overview

Board Certification(s): Pediatrics
Pediatric Hematology-Oncology
Medical/Professional School: Northeastern Ohio Universities College of Medicine, Rootstown
Residency: Pediatrics, Yale-New Haven Hospital , New Haven
Fellowship: Hematology, University of Washington School of Medicine, Seattle

Awards and Honors

Award Name	Award Description	Awarded By	Award Date
	Young Investigator Award - Journal of Clinical Oncology	Journal of Clinical Oncology	Jan. 1, 2009

Publications

WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2011 Feb 20: 704-11

C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.
Blood , 2010 Dec 16: 5638-49

Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
Blood , 2010 Aug 5: 702-10

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
Blood , 2010 Mar 25: 2372-9

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
Blood , 2009 Jun 25: 6558-66

Research Funding

Grant Title	Grantor	Amount	Award Date
SHIP and WT1 alterations as markers of PI3K/Akt activation in pediatric AML	Mary Claire Satterly Foundation	$50,000.00	Nov. 1, 2010
Implications of s-SHIP Expression and SHIP Alterations in AML	American Society of Clinical Oncology Cancer Foundation	$50,000.00	July 1, 2009
Implications of s-SHIP Expression and SHIP Alterations in AML	University of Washington Child Health Research Center	$240,000.00	July 1, 2009

Phoenix A. Ho, MD

Recommendations

Overview

Awards and Honors

Publications

Research Funding

Primary Office

Find a Doctor or Researcher

Sections

Information For

About Us

What’s New

About This Site